Advanced Pancreatic Cancer
Advanced metastatic pancreatic adenocarcinoma (mPAC) is increasing in frequency, but is still associated with a poor prognosis, with a five-year survival rate less than 5% and median overall survival of 4-6 months. Nearly 85% of patients diagnosed with mPAC have an unresectable disease and limited treatment options.
Revive Research Institute is conducting a clinical trial investigating a new second line treatment to improve quality of life and performance status in patients with advanced pancreatic cancer. The purpose of our study is to establish the maximum tolerated dose of the investigational drug in combination with a chemotherapy regimen to reduce the number of adverse events and hospitalizations as well as improve progression and overall survival.
- Adults 18 years of age or older, male or female
- Confirmed pancreatic adenocarcinoma of exocrine pancreas that is metastatic, unresectable, or recurrent
- Have at least one measurable tumor lesion
- Disease progression after one prior Gemzar-based therapy or FOLFIRINOX + Gemzar combination therapy
- Additional Criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.